title: Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.
abstract: OBJECTIVE
  A prognostic index for survival was constructed and validated from patient data from two European Organisation for Research and Treatment of Cancer (EORTC) radiation trials for low-grade glioma (LGG). We sought to independently validate this prognostic index with a separate prospectively collected data set (Intergroup 86-72-51).
  
  
  METHODS
  Two hundred three patients were treated in a North Central Cancer Treatment Group-led trial that randomized patients with supratentorial LGG to 50.4 or 64.8 Gy. Risk factors from the EORTC prognostic index were analyzed for prognostic value: histology, tumor size, neurologic deficit, age, and tumor crossing the midline. The high-risk group was defined as patients with more than two risk factors. In addition, the Mini Mental Status Examination (MMSE) score, extent of surgical resection, and 1p19q status were also analyzed for prognostic value.
  
  
  RESULTS
  On univariate analysis, the following were statistically significant (p<0.05) detrimental factors for both progression-free survival (PFS) and overall survival (OS): astrocytoma histology, tumor size, and less than total resection. A Mini Mental Status Examination score of more than 26 was a favorable prognostic factor. Multivariate analysis showed that tumor size and MMSE score were significant predictors of OS whereas tumor size, astrocytoma histology, and MMSE score were significant predictors of PFS. Analyzing by the EORTC risk groups, we found that the low-risk group had significantly better median OS (10.8 years vs. 3.9 years, p<0.0001) and PFS (6.2 years vs. 1.9 years, p<0.0001) than the high-risk group. The 1p19q status was available in 66 patients. Co-deletion of 1p19q was a favorable prognostic factor for OS vs. one or no deletion (median OS, 12.6 years vs. 7.2 years; p=0.03).
  
  
  CONCLUSIONS
  Although the low-risk group as defined by EORTC criteria had a superior PFS and OS to the high-risk group, this is primarily because of the influence of histology and tumor size. Co-deletion of 1p19q is a prognostic factor. Future studies are needed to develop a more refined prognostic system that combines clinical prognostic features with more robust molecular and genetic data.
authors.affiliation: Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: Thomas B
authors.initials: TB
authors.lastname: Daniels
authors.forename: Paul D
authors.initials: PD
authors.lastname: Brown
authors.forename: Sara J
authors.initials: SJ
authors.lastname: Felten
authors.forename: Wenting
authors.initials: W
authors.lastname: Wu
authors.forename: Jan C
authors.initials: JC
authors.lastname: Buckner
authors.forename: Robert M
authors.initials: RM
authors.lastname: Arusell
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Curran
authors.forename: Ross A
authors.initials: RA
authors.lastname: Abrams
authors.forename: David
authors.initials: D
authors.lastname: Schiff
authors.forename: Edward G
authors.initials: EG
authors.lastname: Shaw
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001254:Astrocytoma / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000523:psychology / Q000628:therapy; D001932:Brain Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005260:Female; D005910:Glioma / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D015173:Supratentorial Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D047368:Tumor Burden; D055815:Young Adult